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The activation of Translocator protein (18 kDa) (TSPO) has been demonstrated to mediate rapid anxiolytic efficacy in
stress response and stress-related disorders. This protein is involved in the synthesis of endogenous neurosteroids
that promote γ-aminobutyric acid (GABA)-mediated neurotransmission in the central neural system. However, little
is known about the functions and the underlying mechanisms of TSPO in chronic pain-induced anxiety-like behaviors.
The novel TSPO ligand N-benzyl-N-ethyl-2-(7,8-dihydro-7-benzyl-8-oxo-2-phenyl-9H-purin-9-yl) acetamide (ZBD-2) was
used in the present study. We found that ZBD-2 (0.15 or 1.5 mg/kg) significantly attenuated anxiety-like behaviors in
mice with chronic inflammatory pain induced by hindpaw injection of complete Freund’s adjuvant (CFA). However, the
treatment did not alter the nociceptive threshold or inflammation in the hindpaw. Hindpaw injection of CFA induced
the upregulation of TSPO, GluR1-containing α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors,
and NR2B-containing N-methyl-D-aspartate (NMDA) receptors in the basolateral amygdala (BLA). ZBD-2 administration
reversed the alterations of the abovementioned proteins in the BLA of the CFA-injected mice. Electrophysiological
recording revealed that ZBD-2 could prevent an imbalance between excitatory and inhibitory transmissions in the
BLA synapses of CFA-injected mice. Therefore, as the novel ligand of TSPO, ZBD-2 induced anxiolytic effects, but did
not affect the nociceptive threshold of mice under chronic pain. The anxiolytic effects of ZBD-2 were related to the
regulation of the balance between excitatory and inhibitory transmissions in the BLA.
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The translocator protein (18 kD) (TSPO) is mainly located
in the outer mitochondrial membrane in peripheral tissues
and the central nervous system (CNS). This protein was
initially identified as a peripheral binding site for diazepam
and later functionally and structurally distinguished from
the central benzodiazepine receptor [1]. It is mainly located
in the outer mitochondrial membrane and favors the
transport of cholesterol to the inner mitochondrial mem-
brane, ultimately promoting neurosteroid synthesis [1].
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unless otherwise stated.Ligands of TSPO such as XBD173, YL-IPA08, and AC-
5216 exert anxiolytic and anti-depressant effects in animal
models [3-5]. Its levels are modulated in anxiety disorders,
such as in stress response [6] and mood disorders [1].
Upregulation of TSPO has been observed in response
to injury and neurodegenerative diseases, such as multiple
sclerosis, amyotrophic lateral sclerosis, Parkinson’s disease,
Huntington’s disease, Alzheimer’s disease, and stroke [7].
However, little is known regarding the roles and the
underlying mechanisms of TSPO in chronic pain-induced
anxiety-like behaviors.
Pain is a multidimensional experience that includes
sensory-discriminative, emotional-affective, and cognitive
components. Chronic pain is usually correlated with allo-
dynia and hyperalgesia [8]. Clinically, patients with chronic
pain have a greater tendency to develop mild psychiatric
disorders [9]. Chronic pain induces the development ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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quality of life [10-12]. Previous studies have shown
that anxiety behavior could be induced by an injection of
complete Freund’s adjuvant (CFA) into the hindpaw of
mice with persistent inflammatory pain [12]. In rats with
CFA-induced monoarthritis, a TSPO agonist retarded or
prevented the development of mechanical allodynia and
thermal hyperalgesia in a dose dependent manner,
thereby suggesting that spinal TSPO is involved in
the development and maintenance of inflammatory pain
behaviors [13].
Glutamate is a major excitatory neurotransmitter in
the CNS. The NR2A- and NR2B-containing N-methyl-
D-aspartate (NMDA) receptors are supposedly linked to
different intracellular cascades and have different roles
in synaptic plasticity [14]. The amygdala is a key component
of the CNS that coordinates negative emotional responses
to threatening stimuli. This structure consists of several
anatomically and functionally distinct nuclei, including the
lateral (LA) and basolateral (BLA) nuclei as well as the
central nucleus (CeA) [15,16]. Studies on amygdala function
have focused on the plasticity at the sensory inputs from
the thalamus and cortex to the LA and BLA [17,18]. In
addition, a balance between excitatory and inhibitory
transmission is critical for physiological anxiety; the
prolonged disturbance of this balance can promote
pathological anxiety-like behaviors [19,20]. Studies
demonstrated that TSPO agonists have anxiolytic effects
that are mediated by endogenous GABAergic neurosteroidsFigure 1 ZBD-2 reduces anxiety-like behaviors. (A) Chemical structures
ZBD-2 (0.15 and 1.5 mg/kg) reversed the time in the open arms in CFA-inje
entries in CFA-injected mice. (D) No difference of the total number of arm
reversed the time in center areas in CFA-injected mice. (F) No difference o
*p < 0.05, **p < 0.01 compared to the control group; #p < 0.05, ##p < 0.01 co[3,21,22]. However, the role of TSPO in modulating the
balance between excitatory and inhibitory transmissions
in the BLA remains unknown.
The present study aimed to investigate the possible
anxiolytic effects of a novel TSPO ligand N-benzyl-N-
ethyl-2-(7,8-dihydro-7-benzyl-8-oxo-2-phenyl-9H-purin-
9-yl) acetamide (ZBD-2; Figure 1A) and to elucidate the
underlying mechanisms. ZBD-2 is a novel ligand for TSPO
synthesized in our laboratory (Chinese patent number
201210047188.6). ZBD-2 is an analog of the XBD173 [3],
one of the ligand of TSPO. ZBD-2 showed high affinity
for TSPO prepared from rat brain mitochondria in
the nanomolar range (Ki = 0.463 nM), comparable to
the affinity of 3H-PK11195, the classic TSPO ligand,
for TSPO (Ki = 0.657 nM) [5]. Here, we report that
the activation of TSPO by ZBD-2 attenuates chronic
pain-induced anxiety-like behaviors by regulating the
balance between GABAergic and glutamatergic trans-
mission in the BLA of hindpaw CFA-injected mice.
Results
Anxiolytic effects of ZBD-2 in mice with CFA-induced
chronic inflammatory pain
Hindpaw CFA injection induced significantly anxiogenic
behaviors that were detected at 21 d post-injection.
In the EPM test, mice spent less time in the open
arms (F (3, 20) = 7.065, p = 0.002, LSD test; Figure 1B), and
the number of open arm entries decreased (F (3, 20) = 4.473,
p = 0.015, LSD test; Figure 1C). The time in the central areaof ZBD-2. (B) EPM test were performed on Day 21 after CFA injection.
cted mice. (C) ZBD-2 (0.15 and 1.5 mg/kg) reversed the open arm
entries in each group. (E) In OF test, ZBD-2 (0.15 and 1.5 mg/kg)
f the total distance traveled in each group. n = 6 in each group,
mpared to the CFA+ saline group.
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3.902, p = 0.024, LSD test; Figure 1E). However, the total
number of arm entries in the EPM tests and the total
distance traveled in the OF tests did not change signifi-
cantly, as compared with the controls (Figure 1D and F).
This observation shows that locomotor activity was not
significantly different between the groups. Administration
of ZBD-2 (0.15 and 1.5 mg/kg) for one week reversed the
anxiety-like behaviors in a dose-dependent manner as
shown by the time spent in the open arm and the number
of open arm entries in the EPM tests (Figure 1B and C) as
well as the time spent in the central area in OF tests
(Figure 1E).
Effect of ZBD-2 on pain perception and inflammation
Subsequently, we determined whether the anxiolytic
effects of ZBD-2 are caused by analgesic activity in
animals with chronic pain. Tactile allodynia and thermal
hyperalgesia were examined during the experimental
period. However, we found that anxiolytic doses of ZBD-2
(0.15 and 1.5 mg/kg) did not reduce mechanical allodynia
(Figure 2A) and thermal hyperalgesia (Figure 2C). The
paw withdrawal threshold or latency was not significantlyFigure 2 Effects of ZBD-2 on pain perception. Mechanical allodynia and
CFA injection. ZBD-2 (0.15 and 1.5 mg/kg) did not change the mechanical
(0.15 and 1.5 mg/kg) did not change the thermal hyperalgesia in the ipsila
edema in CFA-injected hindpaws. n = 6 in each group, **p < 0.01 comparedchanged in the contralateral hindpaw (Figure 2B and D).
Furthermore, ZBD-2 did not reduce chronic inflamma-
tion, as shown by the unchanged edema in CFA-injected
hindpaws (Figure 2E). These results suggested that the
anxiolytic effects of ZBD-2 were not caused by anti-
inflammatory or analgesic activities.
Reversed up-regulation of TSPO by ZBD-2 in the
amygdala
Increased TSPO expression is observed in neurological
disorders, such as traumatic brain injury and inflammation
[23]. Levels of TSPO in the BLA were increased on day 21
after hindpaw CFA injection (F (3, 20) = 7.081, p= 0.002, LSD
test; Figure 3). Treatment of ZBD-2 (0.15 and 1.5 mg/kg)
for one week significantly decreased the upregulation of
TSPO in the BLA (Figure 3). These results indicated that
TSPO expression in the BLA is a response to chronic
painful stimuli.
Effects of ZBD-2 on synaptic proteins expression in
the BLA
An imbalance between the excitatory and inhibitory
transmission in the amygdala promotes emotional disordersthermal hyperalgesia were detected on Day 0, 1, 7, 14 and 21 after
allodynia in the ipsilateral (A) and contralateral hindpaw (B). ZBD-2
teral (C) and contralateral hindpaw (D). (E) ZBD-2 did not reduce
to the control group.
Figure 3 Effects of ZBD-2 on TSPO levels. (A) Representative
results of Western blot analysis for TSPO in the BLA on the Day 21
after hindpaw CFA-injection. (B) ZBD-2 (0.15 and 1.5 mg/kg) for one
week significantly decreased the upregulation of TSPO in the BLA.
n = 6 in each group, **p < 0.01 compared to the control group;
#p < 0.05, ##p < 0.01 compared to the CFA+ saline group.
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excitatory synaptic transmission (Figure 4A). The levels of
NR2A- and NR2B-containing NMDARs (F (3, 20) = 3.118,
p = 0.049, LSD test, Figure 4B; F (3, 20) = 3.313, p = 0.041,
LSD test, Figure 4C) as well as GluR1 (F (3, 20) = 10.864,
p = 0.000, LSD test; Figure 4D) were remarkably increased
after CFA-injection. The critical excitatory synaptic
protein Ca2+ /calmodulin-dependent protein kinase II-α
(CaMKII-α) also significantly increased after CFA injection
(F (3, 20) = 16.874, p = 0.000, LSD test; Figure 4E). Treatment
with ZBD-2 (0.15 and 1.5 mg/kg) for one week significantly
reversed the up-regulation of the abovementioned proteins
in the BLA (Figure 4A–E). However, no significant differ-
ences were observed in the levels of GABAA-α2 and
GAD67, which is a glutamate decarboxylase that is critical
for GABA synthesis (Figure 4F-H).
Effects of ZBD-2 on excitatory synaptic transmissions in
the BLA
To further determine the role of TSPO in the excitatory
synaptic transmissions in the BLA, we performed whole-
cell patch-clamp recordings and recorded miniatureexcitatory postsynaptic currents (mEPSC) in the pyramidal
neurons of BLA after three weeks since the CFA injection
(Figure 5A). The frequency and the amplitude of mEPSC
were significantly increased in the BLA neurons of
CFA-injected mice (F (2, 15) = 5.285, p = 0.018, LSD
test, Figure 5B; F (2, 15) = 10.900, p = 0.001, LSD test, 5C).
ZBD-2 (1.5 mg/kg) could reverse the enhancement of
mEPSCs induced by CFA injection (Figure 5).
Effects of ZBD-2 on inhibitory synaptic transmissions in
the BLA
The GABAA receptor-mediated miniature inhibitory
postsynaptic currents (mIPSC) were recorded in BLA
pyramidal neurons after three weeks of CFA-injection
(Figure 6A and B). The mIPSC frequency could not detect
significant differences among the mice from different
treatment groups. However, the mIPSC amplitude was
significantly decreased in CFA-injected mice (F (2, 15) =
8.856, p = 0.003, LSD test; 6C). Treatment with ZBD-2
(1.5 mg/kg) recovered the mIPSC amplitude alteration
that was induced by CFA injection (Figure 6C).
Discussion
In the present study, pain caused by chronic inflammation
was found to induce pronounced anxiety-like behaviors.
Activation of TPSO with ZBD-2 induced notable anxio-
lytic effects in mice with chronic pain, but did not alter
the nociceptive threshold and the inflammation. The
anxiolytic effects of ZBD-2 were related to the regulation
of synaptic transmission in the BLA.
Patients coping with inflammatory arthritis commonly
develop anxiety [24]. The pathophysiological features
and duration of CFA-induced pain in model organisms
make the study of pain and pain associated behaviors
possible [12]. In the hindpaw CFA-injected mouse model,
chronic pain behaviors were verified by hyperalgesia and
allodynia, whereas the anxiety-like behaviors were assessed
with EPM and OF, which evaluate exploratory behaviors
associated with anxiety. Administration of ZBD-2 (0.15 and
1.5 mg/kg) for one week attenuated anxiety-like behavior in
a dose-dependent manner without affecting the locomotor
activity. The anxiolytic dose of ZBD-2 (0.15 and 1.5 mg/kg)
was similar to XBD173 (0.1, 1, 10 mg/kg in rat) and A C-
5216 (the light/dark box test in rats 0.1–3 mg/kg and, social
interaction test in mice 0.01–0.3 mg kg) [5]. However, the
LD50 of ZBD-2 was over 3 g/kg (unpublished data).
The expression of TSPO increased in mice with chronic
pain. In the healthy nervous system, TSPO is expressed at
low levels in glia, as well as in some populations of
neurons [25]. By contrast, TSPO is highly expressed in the
injured or diseased central or peripheral nervous system
at the lesion sites. In the CNS, TSPO is up-regulated in
microglia, astrocytes, and infiltrating macrophages, as well
as occasionally in neurons [7]. This upregulation may be
Figure 4 Effects of ZBD-2 on protein expression in the BLA. (A) Representative results of Western blot analysis in the BLA on the Day 21 after
hindpaw CFA-injection. (B) ZBD-2 (0.15 and 1.5 mg/kg) for one week slightly decreased the levels of NR2A-containing NMDARs. (C) ZBD-2
(1.5 mg/kg) reversed the upregulation of NR2B-containing NMDARs. (D-E) ZBD-2 (0.15 and 1.5 mg/kg) reversed the upregulation of GluR1 and
CaMKII-α. (F) Representative results of Western blot analysis for GABAA-α2 and GAD67. (G and H) Levels of GABAA-α2 and GAD67 were not altered in
groups. n = 6 in each group, *p < 0.05, **p < 0.01 compared to the control group; #p < 0.05, ##p < 0.01 compared to the CFA+ saline group.
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neurodegenerative diseases. Down-regulation of TSPO
by ligands of TSPO may result from the attenuation
of the compensatory effects. Activation of TSPO is
beneficial for several kinds of neurological diseases by
promoting neurosteroid synthesis [25]. Such diseases
include injury to peripheral nerves or the brain [26],
multiple sclerosis [27], Alzheimer’s disease [28], andpost-traumatic stress disorder [29,30]. The TSPO
agonist Ro5-4864 diminishes mechanical allodynia and
thermal hyperalgesia induced by CFA-induced mono-
arthritis [13] and prevents the first- and second-phase
responses in the formalin test [31]. These data suggest
that activation of TSPO is effective for treatment of
inflammatory pain [32]. However, our findings in the
present study were not consistent with these studies.
Figure 5 Effects of ZBD-2 on mEPSC in the BLA. (A) Representative mEPSCs recorded in pyramidal neurons of BLA at a holding potential
of-70 mV. (B) Cumulative frequency and amplitude histogram of the mEPSCs from the slices in each group. (C) Summery of mEPSCs frequency
(left) and amplitude (right) in control (n = 11 slices/4 mice), CFA-vehicle (n = 10 slices/4 mice), CFA-ZBD-2 (n = 12 slices/4 mice) treated mice.
ZBD-2 (1.5 mg/kg) for one week reversed the increases of mEPSCs frequency and amplitude in CFA-treated mice. *p < 0.05 compared to the
control group; #p < 0.05 compared to the CFA+ saline group.
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activation of TSPO with ZBD-2 did not diminish
the mechanical allodynia and thermal hyperalgesia;
the chronic inflammation ware also not reduced in
CFA-injected hindpaws. The discrepancy may be attributedFigure 6 Effects of ZBD-2 on mIPSC in the BLA. (A) Representative mIP
0 mV. (B) Cumulative frequency and amplitude histogram of the mIPSCs fr
and amplitude (right) in control (n = 12 slices/4 mice), CFA-vehicle (n = 12 s
(1.5 mg/kg) for one week reversed the decreases of mIPSCs amplitude in C
compared to the CFA+ saline group.to the use of different pain models. Hernstadt et al. [13]
showed that TSPO ligands diminished mechanical
allodynia and thermal hyperalgesia in the CFA-induced
monoarthritis model. Present results with the hindpaw
CFA injection induced long-term inflammation in theSCs recorded in pyramidal neurons of BLA at a holding potential of
om the slices in each group. (C) Summery of mIPSCs frequency (left)
lices/4 mice), CFA-ZBD-2 (n = 11 slices/4 mice) treated mice. ZBD-2
FA-treated mice. *p < 0.05 compared to the control group; #p < 0.05
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of mechanical allodynia and thermal hyperalgesia were
applied on the plantar surface of left hindpaw that
was the direct site of CFA injection. However, the site
of CFA injection was tibiotarsal joint in monoarthritis
model. Furthermore, the present data provided the
evidences that ZBD-2 could regulated the synaptic
transmission in the BLA. These results suggested that
the anxiolytic effects of ZBD-2 were not caused by
anti-inflammatory or analgesic activity.
The amygdala is a critical region involved in the
integration of pain and anxiety [33,34]. The GABA
system is well-known to have a major role in the
pathogenesis of anxiety and fear conditioning [35].
The improved excitability of output neurons in the
basolateral amygdala improves aversive conditioning,
whereas decreasing the excitability of these neurons
produces anxiolytic effects [36]. Our previous study
reported that levels of excitatory glutamate receptors
increased, whereas the levels of inhibitory GABA receptors
decreased in the stressed mice with anxiety behavior [20].
In the present study, we found that the activation of
TSPO by ZBD-2 enhanced GABAergic neurotransmission,
whereas ZBD-2 did not affect the levels of GABAA-α2 and
GAD67, which is critical for GABA synthesis. This result is
consistent with the findings that TSPO activation
indirectly enhances the GABAergic neurotransmission
via the generation of GABAergic neurosteroids [3]. In
addition, administration of ZBD-2 reversed the up-
regulation of excitatory glutamate receptors, including
the NR2A- and NR2B-containing NMDARs, GluR1
receptors, and the excitatory synaptic protein CaMKII in
the BLA from CFA-injected mice. CaMKII-mediated phos-
phorylation acutely regulates the function and trafficking
of postsynaptic substrates in response to synaptic activity
[37]. High levels of CaMKII which is response to chronic
pain implies the enhanced excitatory synaptic transmission.
Electrophysiological recording provided further evidence
that activation of TSPO with ZBD-2 maintained the
balance between excitatory and inhibitory synaptic trans-
mission in neural circuits of the amygdala.
In conclusion, the present data provides strong evidence
for the role of ZBD-2 in reducing anxiety-like behavior in
animals with persistent inflammatory pain. ZBD-2 may
play a role in the regulation of pain and anxiety through
endogenous neurosteroid production, which modulates
cellular and receptors components. The underlying
mechanisms involved the regulation of neuronal circuits
in the basolateral amygdala.
Materials and methods
Materials
All chemicals were obtained from Sigma (St. Louis, MO)
unless otherwise stated. ZBD-2 was synthesized at ourLaboratory with the purity of 99.9% and dissolved in
the saline (0.9% NaCl). Rabbit anti-NR2A, mouse
anti-NR2B, and mouse anti-GAD67 antibodies were
purchased from Millipore (Billerica, MA). Mouse
anti-CaMKIIα antibody was purchased from Santa Cruz
Biotech (Santa Cruz, CA, USA). Rabbit anti-GluR1
antibody was purchased from Abcam (Cambridge, UK).
All of the chemicals and reagents used were commercially
available and of standard biochemical quality.Animals
Adult (8 weeks old) male C57BL/6 mice from the Fourth
Military Medical University Experimental Animal Center
were used for the experiments. The animals were housed
in groups with a 12 h light: 12 h dark cycle (light on
7:00 AM) at room temperature (24 ± 2°C), humidity
(50%–60%), the food and water were allowed freely.
Animals were allowed to accommodate to laboratory
conditions for 7 days before the procedure. All behavioral
testing occurred during the light period on the designated
day of experiment. All experimental procedures were
approved by the Animal Ethics Committee of the Fourth
Military Medical University. To induced inflammatory
pain, mice were injected subcutaneously with CFA (10 μl,
50% in saline) into the plantar surface of left hindpaw.
The control mice were injected with the same volume
saline. The paw volume was assessed using a Vernier cali-
per to determine the diameter of edema. Two weeks after
CFA administration, the animals received an orally admin-
istration of vehicle or ZBD-2 (0.15 mg/kg or 1.5 mg/kg)
once a day for 6 days, i.e., from Day 16 to Day 21 after
CFA injection. Behavioral tests were performed during
the experiments. Brain samples for western blot were
dissected immediately after behavior tests on Day 21.Thermal hyperalgesia
Thermal hyperalgesia was assessed by measuring the
latency of paw withdrawal in response to a radiant
heat source [38]. To assess thermal nociceptive responses,
a commercially available plantar analgesia instrument
(BME410A, Institute of Biological Medicine, Academy
of Medical Science, China) was used. Animals were
placed in individual plastic boxes and allowed to ad-
just to the environment for 25 min. Thermal hyper-
algesia was assessed by measuring the paw withdrawal
latency (PWL) in response to a radiant heat source.
The heat source was turned off when the mice lifted
the foot, allowing the measurement of time from
onset of radiant heat application to withdrawal of the
mice’s hindpaw. This time was defined as the PWL.
Left paws were tested at 5 minutes intervals for a
total of five trials. A 20 s cutoff was used to prevent
tissue damage.
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Mice were placed in individual plastic boxes and allowed to
adjust to the environment for 25 min. Using the up-down
paradigm [38], mechanical sensitivity was assessed
with a set of von Frey filaments. Based on preliminary
experiments that characterized the threshold stimulus in
untreated animals, the innocuous 0.4 mN (#2.44) filament,
representing 50% of the threshold force, was used to
detect mechanical allodynia. The filament was applied to
the point of bending six times each to the dorsal surface
of the hindpaw. Positive responses included prolonged
hindpaw withdrawal followed by licking or scratching. For
each time point, the percentage response frequency of
hindpaw withdrawal was expressed as follows: (number of
positive responses)/6 × 100 per hindpaw.
Elevated plus maze (EPM)
The Elevated Plus Maze (EPM) was conducted as described
in a previous report [39]. The apparatus comprised
two open arms (25 × 8 × 0.5 cm) and two closed arms
(25 × 8 × 12 cm) that extended from a common central
platform (8 × 8 cm). The apparatus was elevated to a
height of 50 cm above the floor. Mice were allowed to
habituate to the testing room for 2 days before the test,
and pretreated with gentle handling two times per day to
eliminate nervousness. For each test, individual animals
were placed in the center square, facing an open arm, and
allowed to move freely for 5 min. Mice were videotaped
using a camera fixed above the maze and analyzed with a
video-tracking system. The number of entries and time
spent in each arm were recorded.
Open field test
The open field (OF) test was conducted as described in
a previous report [39]. The apparatus (JL Behv-LAM-
Shanghai jiliang software, china) was a square arena
(30 × 30 × 30 cm) with clear Plexiglas walls and white
floor and was placed inside an isolation chamber with
dim illumination. Mice were placed in the center of the box
and allowed to adjust to the environment for 10 minutes.
Mice were videotaped using a camera fixed above the floor
and analyzed with a video-tracking system. The “center”
field is defined as the central 15 × 15 cm2 area of the open
field, one-fourth of the total area. Each subject was
placed in the center of the open field, and its activity
was measured for 15 min.
Western blot
Western blot analysis was performed as described
previously [39]. Tissue samples from the amygdala were
dissected from the brain slices under the anatomical
microscope. Equal amounts of protein (50 μg) were sepa-
rated and electro transferred onto PDVF membranes
(Invitrogen), which were probed with antibody for TSPO(dilution ratio 1:2000), NR2A (dilution ratio 1:200), and
NR2B (dilution ratio 1:500), GAD67 (dilution ratio
1:1500), CaMKII-α (dilution ratio 1:2000) and GluR1
(dilution ratio 1:300) with β-actin (dilution ratio 1:10000)
as the loading control. The membranes were incubated with
horseradish peroxidase–conjugated secondary antibodies
(anti-rabbit/anti-mouse/anti-goat IgG for the primary anti-
bodies). The densitometric analysis of the Western-blot was
conducted using a ChemiDoc XRS (Bio-Rad, Hercules, CA)
and quantified using Quantity One version 4.1.0 (Bio-Rad)
according to the instructions. For data quantification,
band intensity of each blot was calculated as ratio
relative to β-actin. The intensity ratio of the control group
was set as 100%, and the intensity of other treatment
groups were expressed as percentage to the control group.
Whole-cell patch-clamp recording
Mice were anesthetized with 4% isoflurane in air and
then decapitated. The brains were rapidly removed and
placed into ice cold artificial cerebrospinal fluid (ACSF).
Transverse slices (300 μm) containing the BLA were cut
and transferred to a recovery chamber, and was submerged
in oxygenated (95% O2 and 5% CO2) ACSF at room
temperature. After 1 h of recovery, slices were placed in a
recording chamber on the stage of an Olympus microscope
with infrared digital interference contrast optics for
visualization of whole-cell patch-clamp recordings with an
Axopatch 200B amplifier (Axon Instruments, Union
City, CA, USA). Recordings were performed at room
temperature (21°C–23°C), with continuous perfusion
of ACSF at a rate of 2 ml/min. Miniature EPSCs
(mEPSCs) were recorded from BLA pyramid neurons
clamped at-70 mV with the picrotoxin (20 μM) in the
ACSF. The recording pipettes (3–5 MΩ) were filled with
solution containing the following (in mM): 145K-gluconate,
5 NaCl, 1 MgCl2, 0.2 EGTA, 10 HEPES, 2 Mg-ATP, and 0.1
Na3-GTP, adjusted to pH 7.2 with KOH. TTX (0.5 μM)
was added in the perfusion solution. Miniature inhibitory
postsynaptic currents (mIPSCs) were collected at 0 mV
with the CNQX (20 μM) and AP-5 (50 μM) in the ACSF.
The intracellular solution for mIPSCs was as follows:
102 mM cesium gluconate, 5 mM TEA-Cl, 3.7 mM NaCl,
10 mM BAPTA, 0.2 mM EGTA, 20 mM HEPES,
2 mM Mg-ATP, 0.3 mM Na3GTP, and 2.5 mM QX-314-Br,
adjusted to pH 7.2 with CsOH (280–300 mOsmol). Access
resistance (15–30 MΩ) was monitored throughout the
experiment. Data were discarded if access resistance
changed >15% during an experiment.
Date analyses
Data were presented as the mean and standard errors
of the means (SEM). Statistical analysis of differences
between two groups was performed by independent sam-
ple, two-tailed T test. Data of multiple groups were
Wang et al. Molecular Pain  (2015) 11:16 Page 9 of 10evaluated using one-way analysis of variance (ANOVA)
for post hoc comparisons (SPSS 13.0). Data that passed
the homogeneity test were analyzed by the one-way
ANOVA least significant difference (LSD) test. Data that
did not pass the homogeneity test were analyzed by the
one-way ANOVA Dennett’s T3 test. In all cases, p < 0.05
was considered statistically significant.
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